Skip to main content

Table 2 Pneumonia and treatment characteristics

From: Outcomes associated with bacteremia in the setting of methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study

  Bacteremia +   Bacteremia −   P value
  N % N %  
  93 12.16 % 672 87.84 %  
Pneumonia characteristics
Pre-pneumonia LOS, days      
 Mean [SD] 11.3 [15.0]   8.6 [13.7]   
 Median (IQR) 4.7 (1.1, 15.8)   4.6 (0.9, 11)   0.333
ICU prior to pneumonia 15 16.13 % 94 13.99 % 0.634
Pneumonia type      
 CAP or HCAP 35 37.63 % 218 32.44 % 0.318
 HAP or VAP 58 62.37 % 454 67.56 %
ICU at onset of pneumonia 66 70.97 % 485 72.17 % 0.806
ICU transfer after pneumonia onset 5 5.38 % 19 2.83 % 0.198
No ICU during pneumonia admission 7 7.53 % 73 10.86 % 0.372
Specimen type      
 Bronchial brushing 0 0.00 % 1 0.15 % 0.565
 Bronchial washing 8 8.60 % 33 4.91 %
 Bronchoalveolar lavage 7 7.53 % 55 8.18 %
 Sputum 7 7.53 % 73 10.86 %
 Induced sputum 4 4.30 % 23 3.42 %
 Tracheal aspirate 67 72.04 % 487 72.47 %
Illness severity      
 Mechanical ventilation 71 76.34 % 499 74.26 % 0.705
 Vasopressors 40 43.01 % 228 33.93 % 0.104
 APACHE II (at pneumonia onset)      
  Mean [SD] 17.5 [6.0]   16.1 [6.0]   
  Median (IQR) 16 (13, 22)   16 (12, 20)   0.045
Day of pneumonia onset peak WBC      
 Mean [SD] 15.4 [7.2]   15.3 [12.5]   
 Median (IQR) 14.2 (10.5, 21.2)   13.5 (10, 17.9)   0.232
Day of pneumonia onset peak temperature, C      
 Mean [SD] 38.1 [1.1]   38.1 [1.0]   
 Median (IQR) 38.2 (37.5, 38.9)   38.2 (37.3, 38.8)   0.834
CrCl (at pneumonia onset)      
 Mean [SD] 50.78 ± 31.42   58.84 ± 32.44   0.019
 Median (IQR) 48 (26, 67)   56 (33, 79)  
CrCl > 50 (at pneumonia onset) 43 46.24 % 379 56.40 % 0.065
Treatment characteristics
Time to first drug, hrs      
 Mean [SD] 8.7 [21.7]   17.6 [41.7]   
 Median (IQR) 0.1 (0.1, 4.0)   0.1 (0.1, 18.6)   0.007
Drug      
 Ceftaroline 6 6.45 % 12 1.79 % 0.015
 Daptomycin 13 13.98 % 13 1.93 % <0.001
 Linezolid 47 50.54 % 219 32.59 % 0.001
 Vancomycin 83 89.25 % 559 83.18 % 0.174
Time to drug, hrs      
 Ceftaroline      
  Mean [SD] 582.7 [562.5]   382.1 [653.6]   
  Median (IQR) 448.9 (69.6, 1,180.5)   150.2 (16.6, 440.5)   0.426
 Daptomycin      
  Mean [SD] 172.7 [252.0]   648.7 [874.6]   
  Median (IQR) 54.3 (0.1, 187.7)   430.4 (236.7, 580)   0.017
 Linezolid      
  Mean [SD] 117.3 [171.9]   138.9 [225.8]   
  Median (IQR) 46.5 (12.2, 157.7)   67.3 (23.0, 170.8)   0.280
 Vancomycin      
  Mean [SD] 0.9 [0.3]   0.8 [0.4]   
  Median (IQR) 1 (1, 1)   1 (1, 1)   0.110
Number of anti-MRSA drugs used      
 0 5 5.38 % 85 12.65 % <0.001
 1 36 38.71 % 386 57.44 %
 2 43 46.24 % 187 27.83 %
 3 9 9.68 % 13 1.93 %
 4 0 0.00 % 1 15.00 %
  1. LOS length of stay, SD standard deviation, IQR interquartile range, ICU intensive care unit, CAP community-acquired pneumonia, HCAP healthcare-associated pneumonia, HAP hospital-acquired pneumonia, VAP ventilator-associated pneumonia, APACHE Acute Physiology and Chronic Health Evaluation, WBC white blood cells, CrCl creatinine clearance, MRSA methicillin-resistant Staphylococcus aureus
Back to article page

Critical Care

ISSN: 1364-8535